Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX | BCRX Message Board Posts


BioCryst Pharmaceuticals Inc.

  BCRX website

BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  12747 of 12775  at  6/28/2021 3:49:22 PM  by

mdaddy1234


Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX

Coming from the ARNA board...you understand manipulation.
 
I would suggest a secondary is coming ...
 
Around $15 a share. The "new" owners of Fridays shares get to make some bank first.
 
The BCRX cash cow is alive and well. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1  
   Views: 0 [2]
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


Financial Market Data provided by
.
Loading...